Sight Sciences Announces $30M Series E Round Back to HomeMENLO PARK, CA, Sight Sciences announced the closing of an over $30 million Series E Preferred Stock financing round led by D1 Capital Partners.

Proceeds will be used for continued clinical and operational development and to support commercial expansion for Sight Sciences' OMNI and TearCare products.

"Sight Sciences has introduced two technologies that have fundamentally improved how physicians can treat two of the most prevalent eye diseases.

"We are thrilled to be closing a significant growth investment round with D1," said Jesse Selnick, CFO of Sight Sciences.

"We are extremely excited to partner with D1 over the long term," said Paul Badawi, founder and CEO of Sight Sciences. | To read full story, visit https://startuparound.com/read/1584558006.7373874/Sight-Sciences-Announces-$30M-Series-E-Round?ref=audio_experience